Stock Price Forecast

March 28, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Gilead Sciences, Inc. chart...

About the Company

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.

CEO

Daniel O'Day

Exchange

NASDAQ

Website

https://www.gilead.com/

$7B

Total Revenue

17K

Employees

$91B

Market Capitalization

15.82

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $GILD News

Waltham cancer biotech unveils Gilead deal — and layoffs

21h ago, source:

A Waltham biotech is restructuring its team and reprioritizing its resources around two of its cancer drugs — including one ...

Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program

1d ago, source:

Gilead Sciences, Inc. (Nasdaq: GILD) and Xilio Therapeutics, Inc. (Nasdaq: XLO) today announced an exclusive license ...

Gilead's SNDA For Vemlidy Gets FDA Approval To Treat Chronic HBV Infection In Pediatric Patients

1d ago, source:

Gilead Sciences, Inc. (GILD) announced that the FDA has approved the supplemental new drug application or sNDA to expand ...

Gilead's Aggressive Push Beyond HIV Treatments - Plans To Increase Cancer-Focused CAR-T Treatment Production

on MSN ago, source:

Gilead Sciences Inc’s (NASDAQ:GILD) executive revealed the company’s plans to increase its production of cell therapy cancer ...

Cancer Focused Micro-Cap Xilio Therapeutics Stock Doubles In One Session - Here's Why

on MSN ago, source:

Xilio Therapeutics Inc (NASDAQ:XLO) shares are surging as the company announced an exclusive license agreement with Gilead ...

Gilead Sciences CEO's compensation soars to new heights

10d ago, source:

Gilead Sciences Inc. CEO Daniel O'Day total compensation rose 4.6% year over year to $22.6 million as the expanding cancer ...

Xilio stock jumps on Gilead Sciences license deal

on MSN ago, source:

Gilead Sciences signs exclusive license deal with Xilio Therapeutics for XTX301, an investigational tumor-activated IL-12 ...

FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six

1d ago, source:

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved the ...

Gilead, Takeda Rumored to Have Sights on Iovance

6d ago, source: AOL

The company appears to be a good fit for both Gilead Sciences Inc. (NASDAQ:GILD) and Takeda Pharmaceutical Co. (NYSE:TAK), as ...

Assembly Biosciences, Inc.: Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights

4h ago, source:

Four candidates planned to be in clinical development in 2024 with interim data from two studies anticipated by year end Clinical development timelines accelerated for ABI-5366; now anticipating inter ...

Gilead, Xilio Announce Exclusive License Agreement For Tumor-Activated IL-12 Program XTX301

1d ago, source:

Gilead Sciences, Inc. (GILD) and Xilio Therapeutics, Inc. (XLO) announced an exclusive license agreement on Thursday to collaborate ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...